PE99699A1 - Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante - Google Patents
Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueanteInfo
- Publication number
- PE99699A1 PE99699A1 PE1998000612A PE00061298A PE99699A1 PE 99699 A1 PE99699 A1 PE 99699A1 PE 1998000612 A PE1998000612 A PE 1998000612A PE 00061298 A PE00061298 A PE 00061298A PE 99699 A1 PE99699 A1 PE 99699A1
- Authority
- PE
- Peru
- Prior art keywords
- selective inhibitor
- blocker
- composition including
- serotonin reabsorption
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9714675.7A GB9714675D0 (en) | 1997-07-11 | 1997-07-11 | Novel composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE99699A1 true PE99699A1 (es) | 1999-12-21 |
Family
ID=10815744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000612A PE99699A1 (es) | 1997-07-11 | 1998-07-10 | Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP0996466A2 (xx) |
| JP (1) | JP2002508003A (xx) |
| KR (1) | KR20010021644A (xx) |
| CN (1) | CN1262627A (xx) |
| AP (1) | AP2000001728A0 (xx) |
| AR (1) | AR016128A1 (xx) |
| AU (1) | AU9340198A (xx) |
| BG (1) | BG104119A (xx) |
| BR (1) | BR9810996A (xx) |
| CA (1) | CA2295822A1 (xx) |
| CO (1) | CO4950552A1 (xx) |
| DZ (1) | DZ2556A1 (xx) |
| EA (1) | EA200000112A1 (xx) |
| GB (1) | GB9714675D0 (xx) |
| HU (1) | HUP0003074A3 (xx) |
| ID (1) | ID24191A (xx) |
| IL (1) | IL133869A0 (xx) |
| MA (1) | MA24604A1 (xx) |
| NO (1) | NO20000107L (xx) |
| OA (1) | OA11276A (xx) |
| PE (1) | PE99699A1 (xx) |
| PL (1) | PL338017A1 (xx) |
| SK (1) | SK72000A3 (xx) |
| TR (1) | TR200000074T2 (xx) |
| WO (1) | WO1999002142A2 (xx) |
| ZA (1) | ZA986138B (xx) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7417038B1 (en) | 1998-10-15 | 2008-08-26 | Imperial Innovations Limited | Methods of treating cachexia |
| PL205109B1 (pl) | 1998-11-02 | 2010-03-31 | Elan Pharma Int Ltd | Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie |
| ATE526950T1 (de) | 1999-10-29 | 2011-10-15 | Euro Celtique Sa | Hydrocodon-formulierungen mit gesteuerter freisetzung |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| GB0004003D0 (en) * | 2000-02-22 | 2000-04-12 | Knoll Ag | Therapeutic agents |
| EP2263658A1 (en) | 2000-10-30 | 2010-12-22 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| EP1793818A2 (en) * | 2004-09-17 | 2007-06-13 | Neurocure Ltd. | Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder |
| CN100469356C (zh) * | 2006-09-08 | 2009-03-18 | 山东益康药业有限公司 | 复方阿替洛尔缓释片及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2732335C2 (de) * | 1976-07-27 | 1983-01-20 | Sandoz-Patent-GmbH, 7850 Lörrach | Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten |
| CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| ES2145977T3 (es) * | 1995-08-16 | 2000-07-16 | Lilly Co Eli | Potenciacion de la respuesta de la serotonina. |
| EP0792649A1 (en) * | 1996-02-29 | 1997-09-03 | Eli Lilly And Company | Treatment of sleep disorders |
-
1997
- 1997-07-11 GB GBGB9714675.7A patent/GB9714675D0/en active Pending
-
1998
- 1998-07-07 CN CN98806975A patent/CN1262627A/zh active Pending
- 1998-07-07 EA EA200000112A patent/EA200000112A1/ru unknown
- 1998-07-07 HU HU0003074A patent/HUP0003074A3/hu unknown
- 1998-07-07 CA CA002295822A patent/CA2295822A1/en not_active Abandoned
- 1998-07-07 EP EP98946294A patent/EP0996466A2/en not_active Withdrawn
- 1998-07-07 KR KR1020007000202A patent/KR20010021644A/ko not_active Application Discontinuation
- 1998-07-07 WO PCT/EP1998/004971 patent/WO1999002142A2/en not_active Application Discontinuation
- 1998-07-07 SK SK7-2000A patent/SK72000A3/sk unknown
- 1998-07-07 ID IDW20000035A patent/ID24191A/id unknown
- 1998-07-07 BR BR9810996-0A patent/BR9810996A/pt not_active Application Discontinuation
- 1998-07-07 JP JP50818599A patent/JP2002508003A/ja active Pending
- 1998-07-07 AU AU93401/98A patent/AU9340198A/en not_active Abandoned
- 1998-07-07 TR TR2000/00074T patent/TR200000074T2/xx unknown
- 1998-07-07 PL PL98338017A patent/PL338017A1/xx unknown
- 1998-07-07 AP APAP/P/1999/001728A patent/AP2000001728A0/en unknown
- 1998-07-07 IL IL13386998A patent/IL133869A0/xx unknown
- 1998-07-08 DZ DZ980166A patent/DZ2556A1/xx active
- 1998-07-10 ZA ZA9806138A patent/ZA986138B/xx unknown
- 1998-07-10 CO CO98039260A patent/CO4950552A1/es unknown
- 1998-07-10 PE PE1998000612A patent/PE99699A1/es not_active Application Discontinuation
- 1998-07-10 MA MA25165A patent/MA24604A1/fr unknown
- 1998-07-10 AR ARP980103371A patent/AR016128A1/es unknown
-
2000
- 2000-01-10 NO NO20000107A patent/NO20000107L/no not_active Application Discontinuation
- 2000-01-11 OA OA1200000006A patent/OA11276A/en unknown
- 2000-02-01 BG BG104119A patent/BG104119A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1262627A (zh) | 2000-08-09 |
| BG104119A (en) | 2000-12-29 |
| HUP0003074A2 (hu) | 2001-01-29 |
| WO1999002142A2 (en) | 1999-01-21 |
| KR20010021644A (ko) | 2001-03-15 |
| NO20000107D0 (no) | 2000-01-10 |
| AP2000001728A0 (en) | 2000-03-31 |
| AU9340198A (en) | 1999-02-08 |
| WO1999002142A3 (en) | 1999-04-15 |
| HUP0003074A3 (en) | 2001-12-28 |
| OA11276A (en) | 2003-07-31 |
| JP2002508003A (ja) | 2002-03-12 |
| NO20000107L (no) | 2000-01-10 |
| PL338017A1 (en) | 2000-09-25 |
| EP0996466A2 (en) | 2000-05-03 |
| EA200000112A1 (ru) | 2000-10-30 |
| CA2295822A1 (en) | 1999-01-21 |
| SK72000A3 (en) | 2000-12-11 |
| CO4950552A1 (es) | 2000-09-01 |
| ID24191A (id) | 2000-07-13 |
| ZA986138B (en) | 2000-01-10 |
| GB9714675D0 (en) | 1997-09-17 |
| MA24604A1 (fr) | 1999-04-01 |
| AR016128A1 (es) | 2001-06-20 |
| IL133869A0 (en) | 2001-04-30 |
| TR200000074T2 (tr) | 2000-05-22 |
| DZ2556A1 (fr) | 2003-02-15 |
| BR9810996A (pt) | 2000-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR199700522A2 (xx) | Mirtazapin ve bir ya da daha �ok se�i�i serotonin tekrar-emme inhibit�rlerini i�eren farmas�tik bile�im. | |
| CO4900058A1 (es) | Terapia de combinacion para el tratamiento de psicosis | |
| PE99699A1 (es) | Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante | |
| BR0008958A (pt) | Inibidores de reabsorção de monoamina para otratamento de distúrbios do snc | |
| AR031822A1 (es) | Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular. | |
| JP2005532372A5 (xx) | ||
| ZA200509542B (en) | Combination of an NDMA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | |
| ES2153410T3 (es) | Elemento aislante de pared, piso o fachada y sistema para renovacion de aire. | |
| NO20053088L (no) | Farmasoytisk preparat inneholdende en beta-3-adrenoseptoragonist og en serotonin og/eller norepinefrin-gjenopptakelsesinhibitor og anvendelse av nevnte preparat for behandling av blaeredysfunksjon. | |
| MX2007000009A (es) | Forma farmaceutica oral, protegida frente al abuso. | |
| ATE319464T1 (de) | Diätetische nahrungsergänzung zur unterstützung des zerebrovaskulären tonus | |
| CL2007002358A1 (es) | Sistema de liberacion farmaceutica controlado, oral que comprende uno o mas modificadores de ph, una capa aislante; procedimiento de preparacion; y su uso para el tratamiento de trastornos del sistema nervioso central, sistema afectivo, del sueno y s | |
| MY152919A (en) | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
| Li et al. | Additive antidepressant-like effects of fasting with imipramine via modulation of 5-HT2 receptors in the mice | |
| Yamadera et al. | Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects | |
| BRPI0411665A (pt) | uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina | |
| Murphy et al. | Chronic exposure of rats to cognition enhancing drugs produces a neuroplastic response identical to that obtained by complex environment rearing | |
| PA8571901A1 (es) | Nueva composicion farmaceutica | |
| Ekiza | Radical rock: Identities and utopias in Basque popular music | |
| AR017884A1 (es) | Proceso para preparar una composicion farmaceutica que comprende zafirlukast, dicha composicion farmaceutica y metodo para tratar pacientes usando lacomposicion | |
| JP2007505156A5 (xx) | ||
| Nishio et al. | Role of the lipoxygenase pathway in phenylephrine-induced vascular smooth muscle cell proliferation and migration | |
| RS51669B (en) | NEW DRUG COMBINATIONS AS ANTIDEPRESSIVE | |
| SG154337A1 (en) | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
| Muessig | Medieval Preaching |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |